All products have special prices for bulk purchase, please contact for more details if required.

Cat. No.: FrCas9-100 (for 100pmol)

Cat. No.: FrCas9-500 (for 500pmol)

Cat. No.: FrCas9-2500 (for 2500pmol)

Description

FrCas9 is a novel type II‑A CRISPR‑Cas9 nuclease derived from Faecalibaculum rodentium, adding an important new member to the genome‑editing toolbox. The protein consists of 1,372 amino acids and is distinguished by its unique palindromic PAM recognition sequence, 5'-NNTA-3'. This simple dinucleotide core PAM not only greatly expands the range of editable genomic sites but also confers a remarkable capability—direct targeting of TATA‑box elements in eukaryotic promoters.

The TATA‑box is a key component of core promoters and plays a central role in transcription initiation. FrCas9’s ability to target this region provides a powerful new tool for studying TATA‑box–associated gene regulation and exploring potential therapeutic strategies for related diseases.

FrCas9 maintains editing efficiencies comparable to, or even exceeding, those of SpCas9 while exhibiting substantially reduced off‑target activity. High‑throughput assays such as GUIDE‑seq and AID‑seq demonstrate that FrCas9 generates far fewer off‑target sites and shows markedly lower tolerance to mismatches, reflecting its enhanced target‑recognition specificity.